Company Analysis

aTyr Pharma, Inc. (ATYR)

Nasdaq: ATYR · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2005
Grade3.7
◀ Past 2.4● Present 4.8▶ Future 3.5
1 est.

Who runs aTyr Pharma, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Shukla Sanjay
President and CEO. First filing Apr 2016, latest Feb 4, 2026, 13 filings in all.
Officers reporting now
4
of 10 people with a filing in the last fifteen months
Directors reporting now
6
30 people on the record since 2015
Officerssales are open-market, Oct 1, 2025 to Oct 1, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Yaras BrandonChief Financial OfficerOct 2026Oct 1, 2026none
Shukla SanjayPresident and CEOApr 2016Feb 4, 20261 · $0.00
Broadfoot Jill MarieChief Financial OfficerAug 2018Feb 4, 20261 · $0.00
Krueger NancyGeneral CounselMay 2015Feb 4, 20261 · $0.00
Directorssales are open-market, Oct 1, 2025 to Oct 1, 2026
NameRoleFirst filingLatest filingSales, 12 months
Schimmel PauldirectorMay 2015May 28, 2026none
Benevich EricdirectorDec 2024May 13, 2026none
Coughlin TimothydirectorApr 2017May 13, 2026none
Gross Jane AdirectorJul 2019May 13, 2026none
Lucas SvetlanadirectorJul 2019May 13, 2026none
Zaknoen SaradirectorMay 2021May 13, 2026none
Earlier names on the record21, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton ATYR · research, not advice